Systematic review: Preventive and therapeutic applications of metformin in liver disease

查看全文 作　　者：Aparna [1]Bhat;Giada [1]Sebastiani;Mamatha [1]Bhat

机构地区：[1]Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal

出　　处：《World Journal of Hepatology》索引2015年第7卷第12期,共8页

摘　　要：Metformin, a biguanide derivative, is the most commonly prescribed medication in the treatment of type 2 diabetes mellitus. More recently, the use of metformin has shown potential as a preventive and therapeutic agent for a broad spectrum of conditions, including liver disease and hepatic malignancies. In this systematic review,we critically analyze the literature behind the potential use of metformin across the spectrum of liver disease and malignancies. The Pub Med and Ovid MEDLINE databases were searched from 2000 to March 2015, using a combination of relevant text words and MeS H terms: metformin and mammalian target of rapamycin, hepatitis B virus(HBV), hepatitis B virus(HCV), nonalcoholic fatty liver disease(NAFLD), hepatocellular carcinoma(HCC) or cholangiocarcinoma. The search results were evaluated for pertinence to the issue of metformin in liver disease as well as for quality of study design. Metformin has a number of biochemical effects that would suggest a benefit in treating chronic liver diseases, particularly in the context of insulin resistance and inflammation. However, the literature thus far does not support any independent therapeutic role in NAFLD or HCV. Nonetheless, there is Level Ⅲ evidence for a chemopreventive role in patients with diabetes and chronic liver disease, with decreased incidence of HCC and cholangiocarcinoma. The use of metformin seems to be safe in patients with cirrhosis, and provides a survival benefit. Once hepatic malignancies are already established, metformin does not offer any therapeutic potential. In conclusion, there is insufficient evidence to recommend use of metformin in the adjunctive treatment of chronic liver diseases, including NAFLD and HCV. However, there is good evidence for a chemopreventive role against HCC among patients with diabetes and chronic liver disease, and metformin should be continued in patients even with cirrhosis to provide this benefit. 关键词：Non-alcoholic FATTY liver disease METFORMIN CHEMOPREVENTION Hepatocellular carcinoma HEPATITISC

相关文献

参考文献（64）
引证文献（21）
耦合文献（14）

参考文献(64)

引证文献(21)

耦合文献(14)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Systematic review: Preventive and therapeutic applications of metformin in liver disease

参考文献(64)

引证文献(21)

耦合文献(14)

用户提示